AstraZeneca PLC (ST:AZN) shares rose 2.8% Friday after the company announced that tozorakimab met its primary endpoint in two Phase III clinical trials for chronic obstructive pulmonary disease. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results